Four Hyaluronic Acid Fillers for Lip Augmentation

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Status: Completed

Conditions: Lip

Treatments: Procedure: Cosmetic lip augmentation

Study type: Interventional

Funder types: Other

Identifiers

NCT04362891

NL73349.029.20

Details and patient eligibility

About

There is need for evidence-based and reproducible data comparing the safety, longevity and patient satisfaction propensity of the various HA soft tissue filler products. Among cosmetic HA soft tissue filler procedures, especially the lip augmentation has become common. Therefore, the aim of this study is to determine whether a statistically significant difference can be detected in the safety, longevity and/or patient satisfaction related to four HA soft tissue filler products widely used for cosmetic lip augmentation. Specifically, the aim of this study is to determine whether superiority of one or more product(s) over the others can be detected.

Full description

Rationale: Currently, hyaluronic acid (HA) soft tissue fillers are widely employed in cosmetic medical practice for facial contouring and rejuvenation. Among these procedures, especially the lip augmentation has become common. To this end various products have become commercially available, however to date no robust evidence is available to support the safety, longevity or patient satisfaction propensity superiority of one product over the others.

Objective: To assess whether superiority in safety, longevity and patient satisfaction propensity can be shown of one of four most frequently used FDA-approved and/or CE marked HA fillers worldwide, used to augment the lip, over the others.

Study design: Multi-center, randomized, controlled, four group, parallel, triple-blind clinical trial of 160 adult participants.

Study population: Consecutive healthy individuals with no history of previous lip treatment and a self-reported wish for lip augmentation, who present at one of the private cosmetic medicine clinics in the Netherlands, will be recruited.

Intervention (if applicable): After giving informed consent, participants will be randomized to receive a protocoled lip augmentation procedure by the injection of either 1 mL of brand A, B, C or D.

Main study parameters/endpoints: The primary outcome measure will be the absolute lip volume augmentation as measured by the Lemperle Lip Index from baseline to 3-months follow-up. Secondary outcomes will include the incidence of serious adverse reactions and side effects related to the procedure, the absolute volume augmentation from baseline to 2-weeks follow-up and self-reported quality of life and satisfaction with aesthetic results from baseline to 2-weeks follow-up as measured by validated FACE-Q questionnaire scores.

Enrollment: 143 patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18 years or over.
• Female sex.
• No history of previous lip augmentation treatment.
• Oral and written informed consent to participate in the study.
• Desire for cosmetic lip augmentation to improve one's physical or mental well-being.
• Actively treatment seeking (patient actively chooses to make an appointment at a Faceland private cosmetic clinic without invitation).
• Small to moderately full lip volume (Merz Lip Scale score 0 - 2 out of 4).

Exclusion criteria

• Active peri-oral infection in vicinity of injection site
• Tumour in vicinity of injection site
• Active tuberculosis
• Pregnant or breast-feeding
• History of severe hypersensitivity to filler components (sodium hyaluronate preparations or local anesthetics of the -amide type, gram-positive proteins, wasps/bees or the hyaluronidase enzyme)
• Active collagenosis (e.g., active systemic lupus)
• Graft vs. host disease
• Active Hashimoto's disease
• Use of thrombolytics or anticoagulants with high bleeding risk
• General infection
• Porphyria
• Untreated epilepsy
• Keloid tendency
• Cardiac arrythmia
• Severe liver or kidney disease
• Fulfilling the DSM-5 diagnostic criteria for Body Dyspmorphic Disorder
• Concurrent laser- peeling- or dermabrasia treatment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

143 participants in 4 patient groups

Juvéderm®

Experimental group

Description:

Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).

Treatment:

Procedure: Cosmetic lip augmentation

Restylane®

Experimental group

Description:

Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).

Treatment:

Procedure: Cosmetic lip augmentation

Belotero®

Experimental group

Description:

Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).

Treatment:

Procedure: Cosmetic lip augmentation

Stylage®

Experimental group

Description:

Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).

Treatment:

Procedure: Cosmetic lip augmentation